Patient ID document for DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) or DARZALEX® (daratumumab)

Name: 

I am being treated with one of the following medications:
DARZALEX FASPRO™ or DARZALEX®, antibody products for the treatment of multiple myeloma.

Dear Healthcare Professional,

Daratumumab, the anti-myeloma ingredient in DARZALEX FASPRO™ and DARZALEX®, binds to CD38 on red blood cells (RBCs), which results in a positive Indirect Antiglobulin Test (Indirect Coombs test). This may interfere with the ability to accurately detect antibodies to minor histocompatibility antigens in the patient’s serum. Daratumumab-mediated positive Indirect Antiglobulin Tests may persist for up to 6 months after the last DARZALEX FASPRO™ or DARZALEX® treatment. The determination of a patient’s ABO and Rh blood type are not impacted.

You can learn more at darzalexhcp.com/blood-type.

In case of emergency, or if you find this document, please call the contact listed below:

Doctor, clinic, center, or hospital name: 

24-hour emergency telephone number: